Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Wataru Munakata & Kensei Tobinai. (2016) The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma. Expert Opinion on Drug Discovery 11:11, pages 1123-1130.
Read now
Read now
Enrico Derenzini, Pier Luigi Zinzani & Bruce D. Cheson. (2014) Bendamustine: role and evidence in lymphoma therapy, an overview. Leukemia & Lymphoma 55:7, pages 1471-1478.
Read now
Read now
M. Hewitt, S. J. Enoch, J. C. Madden, K. R. Przybylak & M. T. D. Cronin. (2013) Hepatotoxicity: A scheme for generating chemical categories for read-across, structural alerts and insights into mechanism(s) of action. Critical Reviews in Toxicology 43:7, pages 537-558.
Read now
Read now
Articles from other publishers (13)
Nobuhiko Nakamura, Senji Kasahara, Junichi Kitagawa, Hiroshi Nakamura, Michio Sawada, Kenji Fukuno, Yuhei Shibata, Yuto Kaneda, Takeshi Hara, Nobuhiro Kanemura, Hisashi Tsurumi & Masahito Shimizu. (2022) A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma. Experimental Hematology & Oncology 11:1.
Crossref
Crossref
Therasa Kim, He Yun Choi, Hyun-Seo Lee, Sung-Hoon Jung, Jae-Sook Ahn, Hyeoung-Joon Kim, Je-Jung Lee, Hee-Doo Yoo & Deok-Hwan Yang. (2018) Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL). BMC Cancer 18:1.
Crossref
Crossref
Maria Chiara Tisi, Rossella Paolini, Francesco Piazza, Erika Ravelli, Cristina Tecchio, Roberto Sartori, Barbara Famengo, Emanuele Stefano Giovanni D'Amore, Giuseppe Carli, Omar Perbellini, Eros Di Bona, Marco Ruggeri & Carlo Visco. (2018) Rituximab, bendamustine and cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma. American Journal of Hematology 93:12, pages E386-E389.
Crossref
Crossref
Thomas Noesslinger, Michael Panny, Ralph Simanek, Michaela Moestl, Alexandra Boehm, Elisabeth Menschel, Elisabeth Koller & Felix Keil. (2018) High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity. European Journal of Haematology 101:3, pages 326-331.
Crossref
Crossref
Anna Konstantinovna Smol'yaninova, N.G. Gabeeva, S.A. Tatarnikova, A.V. Belyaeva, A.M. Kovrigina, E.G. Gemdzhian & E.E. Zvonkov. (2018) Effectiveness of the Initial Escalation of Immunochemotherapy in Patients with High Risk MALT-Lymphoma: Pilot Study Results. Clinical oncohematology 11:4, pages 338-348.
Crossref
Crossref
Elena Aleksandrovna Stadnik, N.S. Timofeeva, V.V. Strugov & A.Yu. Zaritskii. (2018) Ibrutinib in the Treatment of Relapsed Chronic Lymphocytic Leukemia. Clinical oncohematology 11:1, pages 42-49.
Crossref
Crossref
Carlo Visco, Annalisa Chiappella, Luca Nassi, Caterina Patti, Simone Ferrero, Daniela Barbero, Andrea Evangelista, Michele Spina, Annalia Molinari, Luigi Rigacci, Monica Tani, Alice Di Rocco, Graziella Pinotti, Alberto Fabbri, Renato Zambello, Silvia Finotto, Manuel Gotti, Angelo M Carella, Flavia Salvi, Stefano A Pileri, Marco Ladetto, Giovannino Ciccone, Gianluca Gaidano, Marco Ruggeri, Maurizio Martelli & Umberto Vitolo. (2017) Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. The Lancet Haematology 4:1, pages e15-e23.
Crossref
Crossref
Shoko Goto, Hiroaki Goto & Tomoko Yokosuka. (2016) The combination effects of bendamustine with antimetabolites against childhood acute lymphoblastic leukemia cells. International Journal of Hematology 103:5, pages 572-583.
Crossref
Crossref
Antonio Cuneo, Monia Marchetti, Giovanni Barosi, Atto Billio, Maura Brugiatelli, Stefania Ciolli, Luca Laurenti, Francesca Romana Mauro, Stefano Molica, Marco Montillo, Pierluigi Zinzani & Sante Tura. (2014) Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group. Leukemia Research 38:11, pages 1269-1277.
Crossref
Crossref
Nobuya Hiraoka, Jiro Kikuchi, Takahiro Yamauchi, Daisuke Koyama, Taeko Wada, Mitsuyo Uesawa, Miyuki Akutsu, Shigehisa Mori, Yuichi Nakamura, Takanori Ueda, Yasuhiko Kano & Yusuke Furukawa. (2014) Purine Analog-Like Properties of Bendamustine Underlie Rapid Activation of DNA Damage Response and Synergistic Effects with Pyrimidine Analogues in Lymphoid Malignancies. PLoS ONE 9:3, pages e90675.
Crossref
Crossref
Francesco Zaja, Michael Mian, Stefano Volpetti, Carlo Visco, Cinzia Sissa, Ilaria Nichele, Monica Castelli, Achille Ambrosetti, Simona Puglisi, Renato Fanin, Sergio Cortelazzo, Giovanni Pizzolo, Livio Trentin, Francesco Rodeghiero, Rossella Paolini, Paolo Vivaldi, Rosaria Sancetta, Miriam Isola & Gianpietro Semenzato. (2013) Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice. American Journal of Hematology 88:11, pages 955-960.
Crossref
Crossref
Carlo ViscoSilvia FinottoRenato ZambelloRossella PaoliniAndrea MeninRoberta ZanottiFrancesco ZajaGianpietro SemenzatoGiovanni PizzoloEmanuele S.G. D'AmoreFrancesco Rodeghiero. (2013) Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma Ineligible for Intensive Regimens or Autologous Transplantation. Journal of Clinical Oncology 31:11, pages 1442-1449.
Crossref
Crossref
Carlo Visco, Silvia Finotto, Fabrizio Pomponi, Roberto Sartori, Francesco Laveder, Livio Trentin, Rossella Paolini, Eros Di Bona, Marco Ruggeri & Francesco Rodeghiero. (2013) The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high‐risk patients with chronic lymphocytic leukemia. American Journal of Hematology 88:4, pages 289-293.
Crossref
Crossref